Ascendis Pharma As Stock Performance
| ASND Stock | USD 224.19 2.16 0.97% |
Ascendis Pharma has a performance score of 5 on a scale of 0 to 100. The firm shows a Beta (market volatility) of -0.36, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Ascendis Pharma are expected to decrease at a much lower rate. During the bear market, Ascendis Pharma is likely to outperform the market. Ascendis Pharma AS right now shows a risk of 2.64%. Please confirm Ascendis Pharma AS value at risk, daily balance of power, and the relationship between the total risk alpha and expected short fall , to decide if Ascendis Pharma AS will be following its price patterns.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Ascendis Pharma AS are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, Ascendis Pharma may actually be approaching a critical reversion point that can send shares even higher in March 2026. ...more
Actual Historical Performance (%)
One Day Return 0.97 | Five Day Return 2.97 | Year To Date Return 5.11 | Ten Year Return 1.1 K | All Time Return 1.1 K |
1 | Ascendis Announces Extension of FDA Review Period for TransCon CNP for Children with Achondroplasia | 11/25/2025 |
2 | Ascendis Pharma AS Given New 256.00 Price Target at Stifel Nicolaus | 12/11/2025 |
3 | Does Ascendis Pharma Share Price Reflect Its Strong Multi Year Rally | 01/08/2026 |
4 | Best Growth Stocks To Research January 20th | 01/20/2026 |
5 | Is Positive COACH Data and Priority Review for TransCon CNP Reframing Ascendis Pharmas Investment Case | 01/22/2026 |
6 | VISEN Pharmaceuticals largest shareholders are public companies who were rewarded as market cap surged HK412m last week | 01/23/2026 |
7 | Barclays Initiates Coverage on Ascendis Pharma with Overw - GuruFocus | 01/28/2026 |
8 | BofA Reiterates Buy Rating on Ascendis Pharma While Wells Fargo Analyst Raises PT | 01/29/2026 |
9 | RBC Maintains Outperform Rating on Ascendis Pharma Amid Growth Targets | 01/30/2026 |
10 | Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026 | 02/04/2026 |
11 | Ascendis Pharma Q4 2025 Earnings Preview | 02/10/2026 |
| Begin Period Cash Flow | 392.2 M | |
| Total Cashflows From Investing Activities | 6.9 M |
Ascendis Pharma Relative Risk vs. Return Landscape
If you would invest 20,645 in Ascendis Pharma AS on November 13, 2025 and sell it today you would earn a total of 1,774 from holding Ascendis Pharma AS or generate 8.59% return on investment over 90 days. Ascendis Pharma AS is currently generating 0.1717% in daily expected returns and assumes 2.6383% risk (volatility on return distribution) over the 90 days horizon. In different words, 23% of stocks are less volatile than Ascendis, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Ascendis Pharma Target Price Odds to finish over Current Price
The tendency of Ascendis Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 224.19 | 90 days | 224.19 | about 9.88 |
Based on a normal probability distribution, the odds of Ascendis Pharma to move above the current price in 90 days from now is about 9.88 (This Ascendis Pharma AS probability density function shows the probability of Ascendis Stock to fall within a particular range of prices over 90 days) .
Ascendis Pharma Price Density |
| Price |
Predictive Modules for Ascendis Pharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Ascendis Pharma AS. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Ascendis Pharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Ascendis Pharma is not an exception. The market had few large corrections towards the Ascendis Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Ascendis Pharma AS, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Ascendis Pharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.24 | |
β | Beta against Dow Jones | -0.36 | |
σ | Overall volatility | 9.50 | |
Ir | Information ratio | 0.05 |
Ascendis Pharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Ascendis Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Ascendis Pharma AS can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 363.64 M. Net Loss for the year was (378.08 M) with profit before overhead, payroll, taxes, and interest of 561.21 M. | |
| Ascendis Pharma AS currently holds about 955.15 M in cash with (306.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 17.11. | |
| Ascendis Pharma AS has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from seekingalpha.com: Ascendis Pharma Q4 2025 Earnings Preview |
Ascendis Pharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Ascendis Stock often depends not only on the future outlook of the current and potential Ascendis Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Ascendis Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 57.9 M | |
| Cash And Short Term Investments | 559.5 M |
Ascendis Pharma Fundamentals Growth
Ascendis Stock prices reflect investors' perceptions of the future prospects and financial health of Ascendis Pharma, and Ascendis Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ascendis Stock performance.
| Return On Equity | -8.18 | ||||
| Return On Asset | -0.0769 | ||||
| Profit Margin | (0.36) % | ||||
| Operating Margin | 0.05 % | ||||
| Current Valuation | 13.89 B | ||||
| Shares Outstanding | 61.1 M | ||||
| Price To Earning | (9.10) X | ||||
| Price To Book | 14.55 X | ||||
| Price To Sales | 20.98 X | ||||
| Revenue | 363.64 M | ||||
| Gross Profit | 561.21 M | ||||
| EBITDA | (290.02 M) | ||||
| Net Income | (378.08 M) | ||||
| Cash And Equivalents | 955.15 M | ||||
| Cash Per Share | 17.11 X | ||||
| Total Debt | 856.62 M | ||||
| Debt To Equity | 0.84 % | ||||
| Current Ratio | 9.66 X | ||||
| Book Value Per Share | (3.37) X | ||||
| Cash Flow From Operations | (306.2 M) | ||||
| Earnings Per Share | (4.51) X | ||||
| Market Capitalization | 13.57 B | ||||
| Total Asset | 1.18 B | ||||
| Retained Earnings | (2.56 B) | ||||
| Working Capital | 153 M | ||||
| Current Asset | 125.65 M | ||||
| Current Liabilities | 11.45 M | ||||
About Ascendis Pharma Performance
By analyzing Ascendis Pharma's fundamental ratios, stakeholders can gain valuable insights into Ascendis Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Ascendis Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Ascendis Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 2.8 K | 4.4 K | |
| Return On Tangible Assets | (0.37) | (0.39) | |
| Return On Capital Employed | (1.18) | (1.24) | |
| Return On Assets | (0.37) | (0.39) | |
| Return On Equity | 3.22 | 3.38 |
Things to note about Ascendis Pharma AS performance evaluation
Checking the ongoing alerts about Ascendis Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Ascendis Pharma AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 363.64 M. Net Loss for the year was (378.08 M) with profit before overhead, payroll, taxes, and interest of 561.21 M. | |
| Ascendis Pharma AS currently holds about 955.15 M in cash with (306.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 17.11. | |
| Ascendis Pharma AS has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from seekingalpha.com: Ascendis Pharma Q4 2025 Earnings Preview |
- Analyzing Ascendis Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ascendis Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Ascendis Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ascendis Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ascendis Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ascendis Pharma's stock. These opinions can provide insight into Ascendis Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Ascendis Stock analysis
When running Ascendis Pharma's price analysis, check to measure Ascendis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascendis Pharma is operating at the current time. Most of Ascendis Pharma's value examination focuses on studying past and present price action to predict the probability of Ascendis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascendis Pharma's price. Additionally, you may evaluate how the addition of Ascendis Pharma to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |